210 related articles for article (PubMed ID: 36838758)
1. Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
AbdElmoniem N; H Abdallah M; M Mukhtar R; Moutasim F; Rafie Ahmed A; Edris A; Ibraheem W; Makki AA; M Elshamly E; Elhag R; Osman W; A Mothana R; Alzain AA
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838758
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays.
Uba AI; Hryb M; Singh M; Bui-Linh C; Tran A; Atienza J; Misbah S; Mou X; Wu C
Life Sci; 2024 Feb; 338():122395. PubMed ID: 38181853
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
4. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
5. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90).
Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G
Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503
[TBL] [Abstract][Full Text] [Related]
6. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
[TBL] [Abstract][Full Text] [Related]
7. Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking.
Wang Y; Yang L; Hou J; Zou Q; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Feb; 37(3):649-670. PubMed ID: 29380672
[TBL] [Abstract][Full Text] [Related]
8. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
9. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
10. Marine-Derived Compounds as Potential Inhibitors of Hsp90 for Anticancer and Antimicrobial Drug Development: A Comprehensive In Silico Study.
Ouassaf M; Bourougaa L; Al-Mijalli SH; Abdallah EM; Bhat AR; A Kawsar SM
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138564
[TBL] [Abstract][Full Text] [Related]
11. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
12. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
15. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
19. The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production.
Hsu TJ; Nepali K; Tsai CH; Imtiyaz Z; Lin FL; Hsiao G; Lai MJ; Cheng YW
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299636
[TBL] [Abstract][Full Text] [Related]
20. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
